These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

70 related items for PubMed ID: 30765435

  • 1. Antisense Inhibition of Glucagon Receptor by IONIS-GCGRRx Improves Type 2 Diabetes Without Increase in Hepatic Glycogen Content in Patients With Type 2 Diabetes on Stable Metformin Therapy.
    Morgan ES, Tai LJ, Pham NC, Overman JK, Watts LM, Smith A, Jung SW, Gajdošík M, Krššák M, Krebs M, Geary RS, Baker BF, Bhanot S.
    Diabetes Care; 2019 Apr; 42(4):585-593. PubMed ID: 30765435
    [Abstract] [Full Text] [Related]

  • 2. Antisense Inhibition of Protein Tyrosine Phosphatase 1B With IONIS-PTP-1BRx Improves Insulin Sensitivity and Reduces Weight in Overweight Patients With Type 2 Diabetes.
    Digenio A, Pham NC, Watts LM, Morgan ES, Jung SW, Baker BF, Geary RS, Bhanot S.
    Diabetes Care; 2018 Apr; 41(4):807-814. PubMed ID: 29439147
    [Abstract] [Full Text] [Related]

  • 3. Population pharmacokinetics and pharmacodynamics of IONIS-GCGRRx, an antisense oligonucleotide for type 2 diabetes mellitus: a red blood cell lifespan model.
    Luu KT, Morgan ES, Bhanot S, Geary R, Smith A, Bethune C, Watts L, Henry S, Wang Y.
    J Pharmacokinet Pharmacodyn; 2017 Jun; 44(3):179-191. PubMed ID: 28132162
    [Abstract] [Full Text] [Related]

  • 4. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
    Loomba R, Morgan E, Watts L, Xia S, Hannan LA, Geary RS, Baker BF, Bhanot S.
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):829-838. PubMed ID: 32553151
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of the glucagon receptor antagonist PF-06291874: A 12-week, randomized, dose-response study in patients with type 2 diabetes mellitus on background metformin therapy.
    Kazierad DJ, Chidsey K, Somayaji VR, Bergman AJ, Calle RA.
    Diabetes Obes Metab; 2018 Nov; 20(11):2608-2616. PubMed ID: 29923286
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and Safety of the Glucagon Receptor Antagonist RVT-1502 in Type 2 Diabetes Uncontrolled on Metformin Monotherapy: A 12-Week Dose-Ranging Study.
    Pettus JH, D'Alessio D, Frias JP, Vajda EG, Pipkin JD, Rosenstock J, Williamson G, Zangmeister MA, Zhi L, Marschke KB.
    Diabetes Care; 2020 Jan; 43(1):161-168. PubMed ID: 31694861
    [Abstract] [Full Text] [Related]

  • 7. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
    Ahrén B, Masmiquel L, Kumar H, Sargin M, Karsbøl JD, Jacobsen SH, Chow F.
    Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin.
    Reusch J, Stewart MW, Perkins CM, Cirkel DT, Ye J, Perry CR, Reinhardt RR, Bode BW.
    Diabetes Obes Metab; 2014 Dec; 16(12):1257-64. PubMed ID: 25155146
    [Abstract] [Full Text] [Related]

  • 9. Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials.
    Viney NJ, van Capelleveen JC, Geary RS, Xia S, Tami JA, Yu RZ, Marcovina SM, Hughes SG, Graham MJ, Crooke RM, Crooke ST, Witztum JL, Stroes ES, Tsimikas S.
    Lancet; 2016 Nov 05; 388(10057):2239-2253. PubMed ID: 27665230
    [Abstract] [Full Text] [Related]

  • 10. First proof of pharmacology in humans of a novel glucagon receptor antisense drug.
    van Dongen MG, Geerts BF, Morgan ES, Brandt TA, de Kam ML, Romijn JA, Cohen AF, Bhanot S, Burggraaf J.
    J Clin Pharmacol; 2015 Mar 05; 55(3):298-306. PubMed ID: 25197025
    [Abstract] [Full Text] [Related]

  • 11. Combined metformin and insulin therapy for patients with type 2 diabetes mellitus.
    Ponssen HH, Elte JW, Lehert P, Schouten JP, Bets D.
    Clin Ther; 2000 Jun 05; 22(6):709-18. PubMed ID: 10929918
    [Abstract] [Full Text] [Related]

  • 12. Single and multiple ascending-dose study of glucagon-receptor antagonist RN909 in type 2 diabetes: a phase 1, randomized, double-blind, placebo-controlled trial.
    Gumbiner B, Esteves B, Dell V, Joh T, Garzone PD, Forgie A, Udata C.
    Endocrine; 2018 Nov 05; 62(2):371-380. PubMed ID: 30203123
    [Abstract] [Full Text] [Related]

  • 13. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D, Rendell M, Rosenzweig J, Egan JW, Mathisen AL, Schneider RL.
    Clin Ther; 2000 Dec 05; 22(12):1395-409. PubMed ID: 11192132
    [Abstract] [Full Text] [Related]

  • 14. Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5).
    Skrivanek Z, Gaydos BL, Chien JY, Geiger MJ, Heathman MA, Berry S, Anderson JH, Forst T, Milicevic Z, Berry D.
    Diabetes Obes Metab; 2014 Aug 05; 16(8):748-56. PubMed ID: 24762094
    [Abstract] [Full Text] [Related]

  • 15. Combining the G-protein-coupled receptor 40 agonist fasiglifam with sitagliptin improves glycaemic control in patients with type 2 diabetes with or without metformin: A randomized, 12-week trial.
    Peng XV, Marcinak JF, Raanan MG, Cao C.
    Diabetes Obes Metab; 2017 Aug 05; 19(8):1127-1134. PubMed ID: 28239939
    [Abstract] [Full Text] [Related]

  • 16. Effects on the glucagon response to hypoglycaemia during DPP-4 inhibition in elderly subjects with type 2 diabetes: A randomized, placebo-controlled study.
    Farngren J, Persson M, Ahrén B.
    Diabetes Obes Metab; 2018 Aug 05; 20(8):1911-1920. PubMed ID: 29645341
    [Abstract] [Full Text] [Related]

  • 17. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34-week active-controlled extension.
    Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ.
    Diabetes Obes Metab; 2012 Dec 05; 14(12):1145-54. PubMed ID: 22974280
    [Abstract] [Full Text] [Related]

  • 18. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes.
    Basu R, Shah P, Basu A, Norby B, Dicke B, Chandramouli V, Cohen O, Landau BR, Rizza RA.
    Diabetes; 2008 Jan 05; 57(1):24-31. PubMed ID: 17914032
    [Abstract] [Full Text] [Related]

  • 19. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A, Nauck MA, Balena R.
    Metabolism; 2013 Sep 05; 62(9):1330-9. PubMed ID: 23831441
    [Abstract] [Full Text] [Related]

  • 20. Miglitol combined with metformin improves glycaemic control in type 2 diabetes.
    Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P.
    Diabetes Obes Metab; 2001 Oct 05; 3(5):326-31. PubMed ID: 11703422
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.